Alembic Pharmaceuticals reported a resilient 4% year-on-year revenue growth to INR 1,838 crore for Q4 FY ’26. The company successfully navigated a dynamic global market by focusing on execution, cost discipline, and strategic portfolio expansion. Despite a near-term margin impact from the launch of its U.S. branded business, Alembic remains optimistic about its long-term growth trajectory, projecting low double-digit consolidated revenue growth for the upcoming fiscal year.
Financial Performance Overview
For the fourth quarter of FY ’26, Alembic Pharmaceuticals achieved INR 1,838 crore in revenue from operations. The performance was driven by volume-led growth in API and animal health, alongside new product launches in the U.S. market. EBITDA before R&D stood at INR 455 crore, marking an 8% year-on-year increase with core margins improving to 25%. Reported profit after tax for the quarter was INR 203 crore, benefiting from exceptional items and one-time tax adjustments.
Strategic Business Highlights
The company continues to advance its execution-led model, with significant progress noted in its Indore facility and portfolio renewal. A key strategic pivot this year is the introduction of the U.S. branded business. While this initiative caused a short-term margin drag, management expects operating leverage to offset these launch-phase costs over the next few quarters. Additionally, the company has seen promising early feedback from its first branded launch, Pivya.
FY ’27 Outlook and Capital Allocation
Alembic has set a guidance for low double-digit top-line growth for FY ’27. R&D investments are expected to remain between INR 750 crore and INR 800 crore, prioritizing complex products, NCE-1, and First-to-File opportunities. Capital expenditure for the new year is projected to be between INR 300 crore and INR 350 crore, focused on capacity debottlenecking and maintenance. The management remains committed to strengthening its specialty platforms and maintaining competitive margins through improved asset utilization.
Source: BSE
